[oxford] Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine Administered 24 Months Following a Primary Dose in Adults ≥60 Years of Age |
10
Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producingEnterobacterales: anin vitroevaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol
10
Ionic thermoelectrics goes epidermal theranostics
10
False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report
